Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma.

@article{Casac2008PhaseIS,
  title={Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma.},
  author={Angel Casac{\'o} and Gerardo L{\'o}pez and Ivan Chaman Garcia and Jose A Rodriguez and Rams{\'e}s Fern{\'a}ndez and Javier Figueredo and Leonel Alberto Torres and Alejandro Perera and Juan F. Batista and Ren{\'e} Leyva and Yamil{\'e} Pe{\~n}a and Zaida Amador and Addys Gonz{\'a}lez and B{\'a}rbara Estupi{\~n}{\'a}n and Marcos Coca and Abel Hern{\'a}ndez and M Clap{\'e}s Puig and Marbelia Iglesias and Astrid Hern{\'a}ndez and Mayra Ramos and Leyanis Rodr{\'i}quez and Niurelkis Suarez},
  journal={Cancer biology & therapy},
  year={2008},
  volume={7 3},
  pages={333-9}
}
Radioimmunotherapy (RIT) may improve the management of malignant gliomas. A Phase I clinical trial was performed to evaluate, for the first time, the toxicity and clinical effect of an intracavitary administration of a single dose of Nimotuzumab (h-R3) labeled wit (188)Re. Nimotuzumab is a humanized monoclonal antibody directed against epidermal growth factor receptors. Three patients with anaplastic astrocytoma (AA) and 8 with glioblastoma multiforme (GBM) were intended to be treated with 3 mg… CONTINUE READING